Overview

The marketing authorisation for Exubera has been withdrawn at the request of the marketing authorisation holder.

español (ES) (261.68 KB - PDF)

View

čeština (CS) (404.45 KB - PDF)

View

dansk (DA) (261.44 KB - PDF)

View

Deutsch (DE) (263.12 KB - PDF)

View

eesti keel (ET) (259.54 KB - PDF)

View

ελληνικά (EL) (430.61 KB - PDF)

View

français (FR) (255.85 KB - PDF)

View

italiano (IT) (255.02 KB - PDF)

View

latviešu valoda (LV) (406.88 KB - PDF)

View

lietuvių kalba (LT) (380.17 KB - PDF)

View

magyar (HU) (394.92 KB - PDF)

View

Nederlands (NL) (262.23 KB - PDF)

View

polski (PL) (406.78 KB - PDF)

View

português (PT) (255.5 KB - PDF)

View

slovenčina (SK) (398.6 KB - PDF)

View

slovenščina (SL) (391.05 KB - PDF)

View

Suomi (FI) (259.93 KB - PDF)

View

svenska (SV) (260.49 KB - PDF)

View

Product information

български (BG) (1.32 MB - PDF)

View

español (ES) (946.37 KB - PDF)

View

čeština (CS) (1.1 MB - PDF)

View

dansk (DA) (897.71 KB - PDF)

View

Deutsch (DE) (953.36 KB - PDF)

View

eesti keel (ET) (925.54 KB - PDF)

View

ελληνικά (EL) (1.28 MB - PDF)

View

français (FR) (952.41 KB - PDF)

View

italiano (IT) (1005.16 KB - PDF)

View

latviešu valoda (LV) (1.12 MB - PDF)

View

lietuvių kalba (LT) (1.03 MB - PDF)

View

magyar (HU) (1 MB - PDF)

View

Malti (MT) (1.06 MB - PDF)

View

Nederlands (NL) (897.16 KB - PDF)

View

polski (PL) (1.17 MB - PDF)

View

português (PT) (934.15 KB - PDF)

View

română (RO) (1.24 MB - PDF)

View

slovenčina (SK) (1.11 MB - PDF)

View

slovenščina (SL) (963.27 KB - PDF)

View

Suomi (FI) (881.61 KB - PDF)

View

svenska (SV) (905.45 KB - PDF)

View

Latest procedure affecting product information: II/0015

09/07/2008

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (353.17 KB - PDF)

View

español (ES) (233.55 KB - PDF)

View

čeština (CS) (325.63 KB - PDF)

View

dansk (DA) (230.28 KB - PDF)

View

Deutsch (DE) (231.22 KB - PDF)

View

eesti keel (ET) (231.06 KB - PDF)

View

ελληνικά (EL) (329.88 KB - PDF)

View

français (FR) (231.01 KB - PDF)

View

italiano (IT) (230.85 KB - PDF)

View

latviešu valoda (LV) (327.64 KB - PDF)

View

lietuvių kalba (LT) (304.46 KB - PDF)

View

magyar (HU) (250.02 KB - PDF)

View

Malti (MT) (349.51 KB - PDF)

View

Nederlands (NL) (233.13 KB - PDF)

View

polski (PL) (329.13 KB - PDF)

View

português (PT) (231.34 KB - PDF)

View

română (RO) (318.91 KB - PDF)

View

slovenčina (SK) (326.68 KB - PDF)

View

slovenščina (SL) (321.84 KB - PDF)

View

Suomi (FI) (230.18 KB - PDF)

View

svenska (SV) (231.04 KB - PDF)

View

español (ES) (229 KB - PDF)

View

čeština (CS) (318.18 KB - PDF)

View

dansk (DA) (229.14 KB - PDF)

View

Deutsch (DE) (228.72 KB - PDF)

View

eesti keel (ET) (228.59 KB - PDF)

View

ελληνικά (EL) (316.55 KB - PDF)

View

français (FR) (227.63 KB - PDF)

View

italiano (IT) (228.12 KB - PDF)

View

latviešu valoda (LV) (319.33 KB - PDF)

View

lietuvių kalba (LT) (296.27 KB - PDF)

View

magyar (HU) (313.81 KB - PDF)

View

Nederlands (NL) (227.85 KB - PDF)

View

polski (PL) (313.64 KB - PDF)

View

português (PT) (222.89 KB - PDF)

View

slovenčina (SK) (318.77 KB - PDF)

View

slovenščina (SL) (311.47 KB - PDF)

View

Suomi (FI) (227.48 KB - PDF)

View

svenska (SV) (229.5 KB - PDF)

View

Product details

Name of medicine
Exubera
Active substance
Insulin human
International non-proprietary name (INN) or common name
insulin human
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
A10AF01

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

EXUBERA is indicated for the treatment of adult patients with type 2 diabetes mellitus not
adequately controlled with oral antidiabetic agents and requiring insulin therapy.
EXUBERA is also indicated for the treatment of adult patients with type 1 diabetes mellitus, in
addition to long or intermediate acting subcutaneous insulin, for whom the potential benefits of
adding inhaled insulin outweigh the potential safety concerns (see section 4.4).

Authorisation details

EMA product number
EMEA/H/C/000588
Marketing authorisation holder
Pfizer Limited

Ramsgate Road
Sandwich
Kent
CT13 9NJ
United Kingdom

Marketing authorisation issued
24/01/2006
Revision
6

Assessment history

This page was last updated on

How useful do you find this page?